MA35841B1 - Dérivés de pyrazolopyridine, procédé d'élaboration de ces dérivés, et utilisation thérapeutique de ceux-ci - Google Patents
Dérivés de pyrazolopyridine, procédé d'élaboration de ces dérivés, et utilisation thérapeutique de ceux-ciInfo
- Publication number
- MA35841B1 MA35841B1 MA37174A MA37174A MA35841B1 MA 35841 B1 MA35841 B1 MA 35841B1 MA 37174 A MA37174 A MA 37174A MA 37174 A MA37174 A MA 37174A MA 35841 B1 MA35841 B1 MA 35841B1
- Authority
- MA
- Morocco
- Prior art keywords
- derivatives
- preparing
- therapeutic use
- pyrazolopyridine
- pyrazolopyridine derivatives
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 150000005229 pyrazolopyridines Chemical class 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des dérivés de pyrazolopyridine inhibiteurs du fgf, représentés par la formule générale (i), un procédé d'élaboration de ces dérivés, et l'utilisation thérapeutique de ceux-ci.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1161589A FR2984325A1 (fr) | 2011-12-14 | 2011-12-14 | Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique |
| PCT/EP2012/075328 WO2013087744A1 (fr) | 2011-12-14 | 2012-12-13 | Dérivés de pyrazolopyridine, procédé d'élaboration de ces dérivés, et utilisation thérapeutique de ceux-ci |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35841B1 true MA35841B1 (fr) | 2014-12-01 |
Family
ID=47458918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37174A MA35841B1 (fr) | 2011-12-14 | 2014-07-02 | Dérivés de pyrazolopyridine, procédé d'élaboration de ces dérivés, et utilisation thérapeutique de ceux-ci |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20140350006A1 (fr) |
| EP (1) | EP2791137B1 (fr) |
| JP (2) | JP6214551B2 (fr) |
| KR (1) | KR102012058B1 (fr) |
| CN (2) | CN104114555B (fr) |
| AU (1) | AU2012351712B2 (fr) |
| BR (1) | BR112014014452A2 (fr) |
| CA (1) | CA2857749A1 (fr) |
| CL (1) | CL2014001539A1 (fr) |
| CO (1) | CO7000778A2 (fr) |
| DK (1) | DK2791137T3 (fr) |
| EA (1) | EA027421B1 (fr) |
| ES (1) | ES2719444T3 (fr) |
| FR (1) | FR2984325A1 (fr) |
| HK (1) | HK1198442A1 (fr) |
| IL (1) | IL232906A (fr) |
| MA (1) | MA35841B1 (fr) |
| MX (1) | MX358422B (fr) |
| PH (1) | PH12014501258A1 (fr) |
| PL (1) | PL2791137T3 (fr) |
| PT (1) | PT2791137T (fr) |
| SG (2) | SG11201402851TA (fr) |
| WO (1) | WO2013087744A1 (fr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10138235B2 (en) | 2011-12-14 | 2018-11-27 | Sanofi | Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof |
| FR2984325A1 (fr) * | 2011-12-14 | 2013-06-21 | Sanofi Sa | Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique |
| US20150344855A1 (en) | 2013-01-16 | 2015-12-03 | INSERM (Institut National de la Santé et de la Recherche Médicale | A Soluble Fibroblast Growth Factor Receptor 3 (FGR3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders |
| AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
| US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| CN105073747B (zh) | 2013-03-15 | 2017-06-06 | 普莱希科公司 | 杂环化合物及其应用 |
| CN105283184B (zh) * | 2013-06-14 | 2018-01-26 | 赛诺菲 | 用于治疗膀胱癌的吡唑并吡啶衍生物 |
| WO2016027781A1 (fr) | 2014-08-18 | 2016-02-25 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Sel de dérivé de pyridine monocyclique et son cristal |
| CN114984013A (zh) | 2015-03-25 | 2022-09-02 | 国立癌症研究中心 | 胆管癌治疗剂 |
| WO2017053604A1 (fr) | 2015-09-23 | 2017-03-30 | The Regents Of The University Of California | Composés pyrazolopyridines antiviraux puissants |
| AU2016374441B2 (en) | 2015-12-17 | 2021-10-21 | Eisai R&D Management Co., Ltd. | Therapeutic agent for breast cancer |
| KR102432192B1 (ko) | 2016-07-07 | 2022-08-12 | 화이자 인코포레이티드 | 가용성 섬유아세포 성장 인자 수용체 3(sfgfr3) 폴리펩티드 및 이의 용도 |
| US10717735B2 (en) | 2017-10-13 | 2020-07-21 | Plexxikon Inc. | Solid forms of a compound for modulating kinases |
| CN112105357A (zh) * | 2018-02-16 | 2020-12-18 | Ucb生物制药有限责任公司 | 药用6,5杂双环衍生物 |
| BR112020017922A2 (pt) | 2018-03-28 | 2020-12-22 | Eisai R&D Management Co., Ltd. | Agente terapêutico para carcinoma hepatocelular |
| CN108774224B (zh) * | 2018-04-23 | 2020-10-30 | 浙江大学 | 吡唑并[3,4-b]吡啶类化合物及其制备方法和应用 |
| CN110833556A (zh) * | 2018-08-15 | 2020-02-25 | 广西梧州制药(集团)股份有限公司 | 吡唑并嘧啶衍生物在治疗肝纤维化的用途 |
| WO2020178316A1 (fr) * | 2019-03-05 | 2020-09-10 | Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. S.P.A. | Azaindazoles en 5 ou 7 utilisés comme inhibiteurs de bêta-lactamase |
| CN118791483B (zh) * | 2024-07-01 | 2025-10-21 | 郑州大学 | 一种1H-吡唑并[3,4-b]吡啶类衍生物及其制备方法和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006050076A1 (fr) * | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Composes de pyrrolyle fusionnes substitues par pyrimidinyle et utiles dans le traitement des troubles induits par la kinase |
| DE102004061288A1 (de) * | 2004-12-14 | 2006-06-29 | Schering Ag | 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel |
| AU2006247322A1 (en) * | 2005-05-16 | 2006-11-23 | Irm Llc | Pyrrolopyridine derivatives as protein kinase inhibitors |
| US7541367B2 (en) * | 2005-05-31 | 2009-06-02 | Janssen Pharmaceutica, N.V. | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders |
| FR2889526B1 (fr) * | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| BRPI0716477A2 (pt) * | 2006-09-06 | 2014-03-18 | Hoffmann La Roche | Derivados heteroarila como inibidores de quinase protéica |
| KR20090031122A (ko) * | 2007-09-21 | 2009-03-25 | 주식회사 중외제약 | 인다졸 골격을 함유하는 화합물, 이의 제조방법 및 상기화합물을 함유하는 약제학적 조성물 |
| EP2225256B1 (fr) * | 2007-11-30 | 2013-01-09 | Pfizer Limited | Nouveaux agonistes des récepteurs des glucocorticoïdes |
| WO2010078427A1 (fr) * | 2008-12-30 | 2010-07-08 | Arqule, Inc. | Composés de pyrazolo[3,4-b]pyridine substitués |
| FR2951172B1 (fr) * | 2009-10-13 | 2014-09-26 | Pf Medicament | Derives pyrazolopyridines en tant qu'agent anticancereux |
| SMT201700581T1 (it) * | 2009-12-21 | 2018-01-11 | Samumed Llc | 1h-pirazolo[3,4-b]piridine e loro usi terapeutici |
| WO2012019954A1 (fr) * | 2010-08-12 | 2012-02-16 | Evotec (Uk) Ltd. | Composés pyrazolopyridine en tant qu'inhibiteurs de pde10a |
| FR2984325A1 (fr) * | 2011-12-14 | 2013-06-21 | Sanofi Sa | Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique |
-
2011
- 2011-12-14 FR FR1161589A patent/FR2984325A1/fr active Pending
-
2012
- 2012-12-13 CA CA2857749A patent/CA2857749A1/fr not_active Abandoned
- 2012-12-13 WO PCT/EP2012/075328 patent/WO2013087744A1/fr not_active Ceased
- 2012-12-13 MX MX2014007168A patent/MX358422B/es active IP Right Grant
- 2012-12-13 EP EP12808328.4A patent/EP2791137B1/fr active Active
- 2012-12-13 JP JP2014546500A patent/JP6214551B2/ja active Active
- 2012-12-13 ES ES12808328T patent/ES2719444T3/es active Active
- 2012-12-13 CN CN201280069679.9A patent/CN104114555B/zh active Active
- 2012-12-13 US US14/364,420 patent/US20140350006A1/en not_active Abandoned
- 2012-12-13 SG SG11201402851TA patent/SG11201402851TA/en unknown
- 2012-12-13 KR KR1020147019030A patent/KR102012058B1/ko not_active Expired - Fee Related
- 2012-12-13 DK DK12808328.4T patent/DK2791137T3/en active
- 2012-12-13 CN CN201610708994.1A patent/CN106317056B/zh active Active
- 2012-12-13 PT PT12808328T patent/PT2791137T/pt unknown
- 2012-12-13 AU AU2012351712A patent/AU2012351712B2/en not_active Ceased
- 2012-12-13 EA EA201491149A patent/EA027421B1/ru not_active IP Right Cessation
- 2012-12-13 SG SG10201510204QA patent/SG10201510204QA/en unknown
- 2012-12-13 PL PL12808328T patent/PL2791137T3/pl unknown
- 2012-12-13 BR BR112014014452A patent/BR112014014452A2/pt not_active Application Discontinuation
- 2012-12-13 HK HK14111927.9A patent/HK1198442A1/xx unknown
-
2014
- 2014-06-01 IL IL232906A patent/IL232906A/en active IP Right Grant
- 2014-06-04 PH PH12014501258A patent/PH12014501258A1/en unknown
- 2014-06-11 CL CL2014001539A patent/CL2014001539A1/es unknown
- 2014-07-02 MA MA37174A patent/MA35841B1/fr unknown
- 2014-07-10 CO CO14149160A patent/CO7000778A2/es unknown
-
2017
- 2017-03-07 US US15/451,970 patent/US20170231998A1/en not_active Abandoned
- 2017-07-07 JP JP2017133321A patent/JP2017206544A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501426A1 (en) | Derivatives of betulin | |
| MA35451B1 (fr) | Dérivés de pyrrolopyrimidine et de purine | |
| IN2014CN00989A (fr) | ||
| CR20200286A (es) | DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294) | |
| MX2014001595A (es) | Compuestos de imidazol, composiciones y metodos de uso. | |
| MX2012009602A (es) | Compuesto heterociclico. | |
| MX359329B (es) | Una combinación farmacéutica para usarse en el tratamiento de un paciente que padece diabetes tipo 2. | |
| TN2014000095A1 (en) | Pharmaceutical compositions | |
| EA201491149A1 (ru) | Пиразолопиридиновые производные, способы их получения и их терапевтическое применение | |
| MY187718A (en) | Pharmaceutical formulations | |
| GEP20166483B (en) | Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament | |
| IN2012DN02139A (fr) | ||
| MX390763B (es) | Compuestos de tetraciclina | |
| MA35196B1 (fr) | Dérivés de 2-amino-3-(inidazol-2-yl)-pyridine-4-one et utilisation de ceux-ci comme inhibiteurs de kinases associées au récepteur du vegf | |
| IN2014DN05972A (fr) | ||
| MY178583A (en) | Hydantoin derivative | |
| CY1117011T1 (el) | Παραγωγα αζολιου | |
| MA37999B1 (fr) | Dérivés de macrolide, leur préparation et leur utilisation thérapeutique | |
| MX2013014950A (es) | Compuestos para el tratamiento del cancer asociado con el papilomavirus humano. | |
| WO2012164055A3 (fr) | Nouveaux composés, leur synthèse et leur utilisation dans le traitement de la douleur | |
| MX2013002656A (es) | Nuevo proceso. | |
| UA79385U (ru) | Способ получения производных (((2-r-1,3-тиазол- 4-ил)метил)сульфанил)-азолов | |
| MX345518B (es) | Compuestos analgesicos, metodos, y formulaciones. | |
| NZ622558A (en) | Hiv replication inhibitors |